In the Letter in Reply titled “Considerations in Meta-Analysis of Immunotherapy for Advanced Cancers Other Than Melanoma—Reply,” published online February 1, 2024, there was an error in the text of the final paragraph. “CheckMate 743 (nivolumab + ipilimumab + chemotherapy vs chemotherapy in malignant pleural mesothelioma)” now correctly reads “CheckMate 743 (nivolumab + ipilimumab vs chemotherapy in malignant pleural mesothelioma).” This article was corrected online.
Reference
- 1.Shenoy NK. Considerations in meta-analysis of immunotherapy for advanced cancers other than melanoma—reply. JAMA Oncol. Published online February 22, 2024. doi: 10.1001/jamaoncol.2024.0178 [DOI] [PubMed] [Google Scholar]
